[1]南新记,栗广辉,王志峰.利膈散联合顺铂方案治疗食管癌效果及对患者炎性因子、生活质量和不良反应的影响*[J].陕西中医,2019,(1):58-60.
　NAN Xinji,LI Guanghui,WANG Zhifeng..Effect of Ligesan combined with cisplatin regimen on esophageal cancer patients and its effects on inflammatory factors, quality of life and adverse reactions[J].,2019,(1):58-60.
点击复制

利膈散联合顺铂方案治疗食管癌效果及对患者炎性因子、生活质量和不良反应的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年1期
页码:
58-60
栏目:
临床研究
出版日期:
2019-01-05

文章信息/Info

Title:
Effect of Ligesan combined with cisplatin regimen on esophageal cancer patients  and its effects on inflammatory factors, quality of life and adverse reactions
文章编号:
DOI:10.3969/j.issn.10007369.2019.01.018
作者:
南新记;  栗广辉;  王志峰
河南省驻马店市中医院肿瘤内科(驻马店 463000)
Author(s):
NAN Xinji;  LI Guanghui;  WANG Zhifeng.
Department of Oncology, Zhumadian City Hospital of Henan Province (Zhumadian 463000)
关键词:
利膈散; 顺铂方案; 食管癌; 炎症因子; 生活质量; 不良反应
Keywords:
Key words Ligesan;  Cisplatin regimen;  Esophageal cancer; Inflammatory; Quality of life; Adverse reaction
分类号:
R735.1
文献标志码:
A
摘要:
摘 要 目的：研究利膈散联合顺铂方案对食管癌患者效果及对炎性因子、生活质量和不良反应的影响。方法：选取83例食管癌患者纳入本次研究，以随机法将全部患者分为观察组（42例）与对照组（41例），对照组给予顺铂方案治疗，观察组给予利膈散联合顺铂方案治疗，观察两组患者治疗效果及对炎性因子、生活质量和不良反应的影响。结果：对照组总有效率为65.85%，观察组总有效率为71.43%，与对照组相比，观察组疗效更为优异（P＜0.05）；治疗后两组患者生活质量有所提高，不良反应、炎性水平显著降低，组内对比差异有统计学意义（P＜0.05），而观察组改善程度均优于对照组，组间对比差异有统计学意义（P＜0.05）。结论：利膈散联合顺铂方案对食管癌疗效确切，且对食管癌炎性因子、生存质量和不良反应具有较好的改善程度，值得临床应用。
Abstract:
Abstract Objective: To study the effects of Ligesan combined with cisplatin on esophageal cancer patients and their effects on inflammatory factors, quality of life and adverse reactions. Methods: Eightythree patients with esophageal cancer were randomly divided into observation group (42 cases) and control group (41 cases). The control group was treated with cisplatin regimen. The cisplatin regimen was used to observe the therapeutic effects of the two groups and their effects on inflammatory factors, quality of life and adverse reactions. Results: The total effective rate of the control group was 65.85%, and the total effective rate of the observation group was 71.43%. Compared with the control group, the observation group was more effective (P<0.05). After treatment, the inflammatory factors, quality of life and poorness of the two groups were improved. The response was improved, and the difference in the group was statistically significant (P<0.05), while the improvement of the observation group was better than that of the control group. The difference between the groups was statistically significant (P<0.05). Conclusion: Ligesan combined with cisplatin has a good effect on esophageal cancer, and it has a good improvement on inflammatory factors, quality of life and adverse reactions of esophageal cancer, which is worthy of clinical promotion.

参考文献/References:

[1] 金明根, 姜盛春, 陈智文, 等. 术前同步放化疗与单纯手术治疗食管癌的临床对比观察[J] . 中华肿瘤防治杂志, 2008,15(23):18151817.
[2] 何义富, 胡长路, 徐腾云, 等. 一线应用紫杉醇联合奈达铂治疗晚期食管癌近期疗效观察[J] . 中华肿瘤防治杂志, 2011,18(1):6062.
[3] 李 峰, 周 远, 张立成, 等. 紫杉醇联合放疗同步治疗中晚期食管癌的临床观察[J] .中华肿瘤防治杂志, 2011,18(20):16351638.
[4] 马胜禄, 陈利辉, 刘向军, 等. 小剂量紫杉醇同步后程加速分割放疗治疗93例食管癌的临床研究[J] . 河北医学, 2011,17(6):714717.
[5] 杨 弘, 傅剑华, 胡 玮, 等. 术前放化疗并手术治疗局部晚期食管癌[J] . 中华医学杂志, 2008,88(45):31823185.
[6] 蒋亦燕, 吴式琇, 张 萍, 等. 常规剂量紫杉醇联合顺铂术前同步放化疗治疗胸段食管癌的临床研究[J] . 中华医学杂志, 2008,88(31):21712174.
[7] 靳桂红. Ⅱ～Ⅲ期食管癌治疗模式探讨[J] . 中国煤炭工业医学杂志, 2011,14(12):17511753.
[8] 王书长. 放化疗联合治疗食管癌患者的临床疗效及预后分析[J] . 中国肿瘤临床与康复, 2013,20(9):10121014.
[9] 李 晶, 刘亚娴. 浅谈食管癌的中医治疗[J] . 陕西中医,2006,27(3):318319.〖ZK)〗
[10] 郝 捷, 邵 康. 中国食管癌流行病学现状、诊疗现状及未来对策[J] . 癌症杂志, 2011, 21(7):501504.

备注/Memo

备注/Memo:
* 河南省中医药科技攻关项目（2013ZY01009）
更新日期/Last Update: 2019-03-13